NLRX1 and breast carcinoma: Conversely, NLRX1 has been found to augment tumor progression in an AOM-only model of colon cancer, HPV-induced head and neck squamous cell carcinoma, and ER/PR- breast cancer where it increases disease burden and promotes aggressive phenotypes (31, 32, 39, 40).